Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Follow-up Study of Botaretigene Sparoparvovec for X-linked Retinitis Pigmentosa (RPGR-XLRP)
2020-002255-37Phase 3Terminated
- Sponsor
- MeiraGTx
- Start
- Oct 2021
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botaretigene sparoparvovec in retinitis pigmentosa (RP), sponsored by MeiraGTx. Primary endpoint: Change from baseline in binocular vision-guided mobility assessment (VMA). Started Oct 2021; status: terminated.
02
Drugs
botaretigene sparoparvovec
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on 2020-002255-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002255-37.